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Summary The aim of this study was to assess the effect of a low-dose testosterone
on body composition and pulmonary function, as well as on quality of life, sexuality,
and psychological symptoms in patients with chronic obstructive pulmonary disease
(COPD). Twenty-nine men with moderate to severe COPD were allocated to receive
either 250mg of testosterone or placebo intra-muscularly, every fourth week, during
the 26 weeks study period. Fat-free mass increased in the treatment group
(Po0:05), and a significant difference between the treatment and the control
group was seen after 26 weeks (Po0:05). Fat mass decreased in the treatment group
(Po0:05), and there was a significant difference between the treatment and the
control group after 12 weeks (Po0:01). A significantly better erectile function was
reported in the treatment group at the final visit (Po0:05), and the overall sexual
quality of life was significantly better in the treatment group after 12 weeks
(Po0:05). No improvement in pulmonary function was found. In conclusion,
administration of a low-dose testosterone to men with COPD for 26 weeks was
associated with improvement of body composition, better erectile function and
sexual quality of life. Furthermore, there were no clinical or biochemical side
effects.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Chronic obstructive pulmonary disease (COPD) is a
devastating, debilitating disease afflicting many
millions of people worldwide. There are few
effective therapies for COPD. Bronchodilators and
anti-inflammatory drugs are often used even if the
reversible component of the airway obstruction is
modest. Long-term oxygen therapy (LTOT) has been
shown to improve survival and the quality of life in
severely hypoxic patients.1,2 Pulmonary rehabilita-
tion has been part of the treatment for many years
and seeks to reestablish the patients to the highest
possible level of function, but cannot reverse the
pulmonary abnormalities.3
Individuals with COPD often have progressive
weight loss, and loss of lean body mass has
specifically been associated with skeletal muscle
dysfunction.4,5 Reversal of weight loss has been
found to improve exercise capacity and improve
survival.6,7 Abnormalities in the levels of circulat-
ing testosterone have been described,8,9 suggesting
that substitution with androgens might be a
rational therapy for patients with COPD. Testoster-
one supplementation in men with subnormal levels
of testosterone have been shown to increase fat-
free mass, reduce fat-mass, improve some aspects
of physical, sexual, and cognitive functions, and
improve mood and quality of life,10–12 but for
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patients with COPD the information is scarce. In a
study of 217 patients, administration of nandrolon
in combination with nutritional support and ex-
ercise increased fat-free mass and respiratory
muscle function.13 In another study of 23 men with
stable COPD and a body mass index (BMI) below
20 kg/m2, treatment with stanozolol in combina-
tion with respiratory rehabilitation increased BMI
and lean body mass.14 To our knowledge, no study
has been conducted on the potential effect of
androgen therapy on quality of life and sexuality in
patients with COPD.
In this study, we investigated the effect of a
physiological dose of testosterone on anthropo-
metric measures, body composition and, pulmonary
function, as well as on subjective perceptions of
quality of life, sexuality, and psychological symp-
toms in patients with moderate to severe COPD.
Materials and methods
Patients
Included were 29 ambulatory male patients, from
the pulmonary outpatients clinic, aged 54–75, with
moderate to severe COPD (forced expiratory
volume in 1 sFFEV1o60% of predicted). When
entering the study they were all in stable condi-
tion. Patients with asthma, malignancies, cardiac
impairment or hepatic or endocrine disease were
excluded from participation. The Tromsø Regional
Ethics Committee approved the protocol, and all
participants gave their written informed consent.
The study was performed in accordance with the
recommendations in the Helsinki Declaration.
Study design
The objective was to evaluate the effects of
testosterone treatment, with subjective health
scales, body composition and FEV1 levels as primary
outcome measures. Secondary outcome measures
were sexual function, androgen levels, additional
pulmonary function tests, and performance status.
The patients were randomly allocated in a double-
blind fashion to receive every fourth week either
testosterone treatment (an intra muscular depot
injection of testosterone enanthate 250mg, Primo-
teston-Depot&, Schering, Germany), or placebo (an
intra muscular injection of 0.9% saline solution).
The study period was 26 weeks and each patient
received a total of seven injections. For 2 days at
baseline, 12 and 26 weeks the patients were
admitted to the Clinical Research Unit at the
University Hospital of North Norway for extensive
examinations.
Assessment
A physical examination including a prostate palpa-
tion was performed. A Flowmate-spirometer (Jae-
ger, Germany) was used to estimate forced vital
capacity (FVC) and FEV1 1 h after inhalation of a
bronchodilator. A 6-min walking distance (6-MWD)
was performed with assessment of the Borg score
for breathlessness after walking. Nocturnal oxygen
saturation (23.00–07.00 h) was measured with an N-
100 pulse oxymeter (Nellcor, CA, USA). Blood gases
were analyzed using a CIBA Corning 288 Blood Gas
System analyzer (Medfield, MA, USA). Men with
LTOT continued their oxygen treatment during the
pulmonary function tests.
Height and weight were measured in subjects
wearing light clothing without shoes. BMI was
calculated as weight in kilograms divided by the
square of the height in meters (kg/m2). Body
composition was determined by dual energy X-ray
absortiometry (DEXA) (Lunar Radiation Corp; Madi-
son, Wisconsin, USA). Blood samples including
hemoglobin, hematocrit, cholesterol, HDL-choles-
terol, LDL-cholesterol, triglycerides, prostate spe-
cific antigen (PSA), glucose, testosterone, LH, FSH,
and sex hormone-binding globulin (SHBG) were
collected by venipuncture in a fasting state at
08.00 h and were analyzed using standard labora-
tory procedures at the department of clinical
chemistry. Blood samples were obtained 4 weeks
after injection of study medication at the 12 week
visit and after 2 weeks at the last visit. Free
testosterone values were calculated from total
testosterone and SHBG according to Vermeulen
et al.15
Four questionnaires were completed: (1) the St.
George’s respiratory questionnaire (SGRQ);16 (2)
the Montgomery-Asberg Depression Rating Scale
(MADRS);17 (3) the International Index of Erectile
Function (IIEF-5)18 with a few additional questions
on sexuality; and (4) Rapid Disability Rating Scale-2
(RDRS-2).19 In addition the minimental state ex-
amination (MMSE)20,21 was performed by trained
nurses.
Potential adverse events were recorded every
fourth week, before the injection of study medica-
tion.
Statistical analysis
SPSS (SPSS Inc. SPSS Base 10.1 for Windows
User’s Guide) was used for all analysis. The
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non-parametric Mann–Whitney U-test was used to
determine the differences between the groups
using delta values, and non-parametric Wilcoxon
Signed Ranks Test to determine the changes from
baseline within the groups. No reports of treatment
effects on subjective health status or sexuality
were available for power calculations and estima-
tion of sample size. Therefore, differences in
treatment effects of 1 SD or more were assumed
to be clinically relevant, and 30 patients would
than yield a statistical power of 0.80 to detect such
effects at the 0.05 significance level. Results were
considered statistically significant at Po0:05:
Values are expressed as mean7SD, if nothing else
is noted.
Results
Patients
The clinical characteristics of the patients are
shown in Table 1. There were no significant
differences between the groups at baseline. Of 29
randomized patients, 27 patients completed the
trial, but all completed the examinations at week 12.
One patient in the control group died suddenly
of a probable myocardial infarction and one patient
in the treatment group discontinued the study
when a lung cancer was diagnosed. There were
several episodes of respiratory exacerbations,
bronchitis, and pneumonia in both groups, but
there were no significant differences between the
groups. When justified, patients were treated with
a short course of glucocorticosteroids and/or
antibiotics. No other events that could be related
to treatment were reported. All injections of study
medication were performed by nurses, with 100%
compliance.
Pulmonary function
Spirometry, 6-MWD, PaO2 and PaCO2 showed no
significant changes from baseline in either group
and there were no significant differences between
the groups (Table 2). In the nocturnal oxygen
saturation registration, no changes in the lowest
oxygen saturation (SaO2) and mean 8 h SaO2 from
baseline were seen in either group, and there were
no differences between the groups. In the control
group there was a statistically significant increase
in time with SaO2 below 90% (10.4 vs. 21.3%;
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Table 1 Characteristics of the study population. Data are given as mean (SD).
Control group Treatment group
N ¼ 14 N ¼ 15
Age (years) 67.5 (5.8) 64.5 (6.5)
Range 56–75 54–74
Anthropometrics
Weight (kg) 74.5 (13.4) 71.5 (9.4)
Height (cm) 171.8 (4.6) 173.3 (7.3)
Body mass index (kg/m2) 25.2 (3.7) 23.8 (3.2)
Partner (yes) 11 12
Smoking
Current (yes) 5 6
Years 42 (9) 41 (11)
Pulmonary parameters
PaO2 (kPa) 8.8 (1.0) 9.4 (1.0)
PaCO2 (kPa) 5.7 (1.1) 5.3 (0.5)
FVC (% of predicted) 59.7 (13.2) 71.5 (18.4)
FEV1 (% of predicted) 40.8 (10.4) 43.2 (15.5)
Treatment (n)
LTOT 3 2
Inhaled beta2-agonists 14 15
Inhaled steroids 8 9
Inhaled ipratropium bromide 7 9
Oral theofyllines 5 4
Oral prednisone 2 2
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; LTOT, long-term oxygen therapy. Normal values: PaO2 11.0–
14.0 kPa; PaCO2 4.7–6.0 kPa. There were no significant differences between the control and treatment group.
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Po0:05), but there were no significant differences
between the groups (Table 2).
Anthropometry and DEXA
Body weight did not change significantly during the
study period and there were no differences
between the groups (Fig. 1).
DEXA showed that total body fat mass decreased
compared with baseline in the treatment group, at
12 weeks (1.85%; Po0:01), and at 26 weeks
(1.5%; Po0:05), and there was a significant
difference between the treatment and the control
group after 12 weeks (1.85% vs. 0.09%; Po0:01).
Fat-free mass increased from baseline in the
treatment group at 26 weeks (1.1 kg; Po0:05),
and a significant difference between the treatment
and control group was seen after 26 weeks (1.1 vs.
0.8 kg; Po0:05) (Fig. 1).
Questionnaires
The IIEF-5 score increased non-significantly in the
treatment group (15.1 vs. 17.5) and decreased
significantly in the control group (13.2 vs. 10.7;
Po0:05) from baseline. A significant difference
between the groups was found after 26 weeks
(Po0:05) (Table 3). The overall sexual quality of
life improved non-significantly in the treatment
group, and at 12 weeks the sexual quality of life
was significant better compared to the control
group (Po0:05) (Table 3).
There were no changes in the total SGRQ score or
in any of the three components (symptom, activity
and impact) from baseline in either group, and no
differences between the groups were found. Both
groups scored high on the MMSE at baseline
(treatment group 28:271:6 vs. control group
28:371:6 of maximal 30 points), thus none of the
patients were demented. There were no changes or
differences during the study. None of the patients
had signs of depression in the MADRS score at
baseline or during the study, and there were no
differences between the groups. The RDRS-2 ques-
tionnaire showed that most patients coped well
with activities of daily living, and there were no
differences between the groups at baseline or
during the study period.
Sex hormones and clinical chemistry
The levels of sex hormones and SHBG did not differ
between the groups at baseline. Total and free
testosterone decreased significantly in the control
group (Po0:05) and total testosterone increased in
the treatment group (Po0:05) between baseline
and the final visit. When blood samples were drawn
2 weeks after injection of study medication at the
final visit, there was a difference of both total and
free testosterone between the groups, however, it
did not reach statistical significance (Table 4). In
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Table 2 Blood gas analyses, spirometry, 6-min walking distance, and nocturnal oxygen saturation (23.00–
07.00 h) in control and treatment groups. Data are given as mean (SD).
Control group Treatment group
Baseline Week 12 Week 26 Baseline Week 12 Week 26
Blood gas analyses
PaO2 (kPa) 8.8 (1.0) 9.0 (1.0) 9.2 (1.3) 9.4 (1.0) 9.4 (1.3) 9.5 (1.4)
PaCO2 (kPa) 5.7 (1.1) 5.6 (0.8) 5.8 (0.9) 5.3 (0.5) 5.3 (0.7) 5.2 (0.7)
Spirometry
FVC (% of predicted) 59.7 (13.2) 58.3 (17.0) 64.4 (14.2) 71.5 (18.4) 71.7 (22.3) 77.3 (18.2)
FEV1 (% of predicted) 40.8 (10.4) 40.1 (11.7) 41.2 (12.2) 43.2 (15.5) 42.4 (14.0) 43.6 (13.7)
6-min walking distance
Distance (m) 408 (108) 398 (112) 440 (109) 423 (105) 425 (97) 447 (92)
Lowest SaO2 (%) 86.9 (4.0) 87.8 (3.9) 87.7 (4.3) 88.9 (4.8) 87.7 (5.2) 87.6 (4.0)
Borg score 3.7 (1.5) 3.5 (1.6) 3.5 (1.3) 3.4 (1.8) 3.4 (1.1) 3.3 (1.0)
Nocturnal oxygen saturation
Lowest SaO2 (%) 75.9 (8.7) 82.3 (4.5) 79.5 (5.4) 81.3 (8.1) 82.3 (5.0) 80.6 (7.0)
Mean 8 h SaO2 (%) 92.3 (1.9) 91.6 (2.4) 91.7 (3.1) 91.9 (2.9) 91.5 (2.2) 92.7 (2.6)
Time with SaO2o90 (%) 10.4 (19.9) 20.0 (30.0) 21.3 (33.5)n 11.5 (28.5) 18.4 (31.8) 9.1 (24.4)
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s, LTOT, long-term oxygen therapy; Borg score for breathlessness
attained immediately after walking. Normal values: PaO2 11.0–14.0 kPa; PaCO2 4.7–6.0 kPa.
nPo0:05 compared with baseline.
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the treatment group LH, FSH, and SHBG decreased
significantly during the study compared to baseline
(Po0:01), and significant differences between the
groups at 12 weeks, with lower levels of FSH and
SHBG (Po0:05), and at 26 weeks, for LH (Po0:01),
FSH (Po0:01) and SHBG (Po0:05), were seen
(Table 4).
There were no significant differences in hemo-
globin, hematocrit, PSA, total cholesterol, HDL
cholesterol, LDL cholesterol, and triglycerides
within or between groups during the study.
Discussion
In this randomized, double-blind, placebo-con-
trolled study, we found that administration of
250mg testosterone IM every fourth week to men
with moderate to severe COPD significantly in-
creased fat-free mass, decreased fat mass, and
improved erectile function and sexual quality of
life.
Treatment with testosterone did not affect the
result of the spirometry examination, the level of
PaO2, and the result of the 6-MWD. This is in
agreement with previous studies, where androgen
treatments also were combined with exercise and/
or nutritional support.13,14 However, respiratory
muscle strength measured by maximal inspiratory
mouth pressure (PImax) was reported to improve
significantly in patients receiving androgen,13 but
PImax was not measured in our study.
Supraphysiologic doses of testosterone have been
shown to increase fat-free mass and muscle size
and strength in normal men,22 and administration
of low-dose testosterone to both young and old
hypogonadal men decreases fat mass and increases
fat-free mass.23–25 Increasing fat-free mass was
also found in the two studies of men with COPD
treated with androgens, but no changes in fat mass
were reported.13,14 In agreement with these two
studies we found an increase in fat-free mass, but
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Figure 1 Changes in weight, fat mass, and fat-free
mass, measured by DEXA, in men who received treatment
(&) and who did not (E). Data are given as mean7SEM.
*Po0:05; **Po0:01 comparing delta values with control
group. wPo0:05; zPo0:01 compared with baseline.
Table 3 Comparison of the degree of erectile dysfunction (IIEF-5) and sexual quality of life between the control
and treatment groups. Data are given as mean (SD).
Control group Treatment group
Baseline Week 12 Week 26 Baseline Week 12 Week 26
N ¼ 13 N ¼ 13 N ¼ 11 N ¼ 14 N ¼ 14 N ¼ 13
IIEF-5 (0–25)n 13.2 (7.5) 12.5 (8.3) 10.7 (8.8)w 15.1 (8.7) 16.4 (7.1) 17.5 (6.3)ww
Erection (0–20) 10.4 (5.5) 9.8 (6.3) 8.8 (6.5)w 12.1 (6.8) 12.9 (5.6) 13.9 (4.8)ww
Satisfaction (0–5) 2.7 (2.0) 2.7 (2.2) 2.1 (2.2)w 3.1 (2.0) 3.4 (1.6) 3.5 (1.5)
Sexual quality of life (0–6)y 2.0 (1.4) 2.5 (1.2) 2.5 (1.4) 2.6 (1.7) 1.7 (1.1)ww 2.2 (1.4)
nA higher score is better performance, and a score p7 is classified as severe erectile dysfunction.
yA lower score represents a higher quality of life.
wwPo0:05 comparing delta values with control group.
wPo0:05 compared with baseline.
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we also found a reduction of fat mass. Most of our
patients had a normal BMI and were not selected
because of being malnourished14 or depleted.13 In
patients with a BMIo20 kg/cm2 a further reduction
of an already low percentage of body fat would not
be expected.14 As treatment with testosterone did
not increase weight in our patients, treatment in
our study was mainly associated with an improve-
ment in body composition. The increase in fat-free
mass although significant was modest, but the
patients in our study continued their ordinary life
while participating in the study and no nutritional
or exercise interventions were made. It is likely
that a standardized exercise program and/or
nutritional intervention in combination with tes-
tosterone administration would have increased the
fat-free mass even more. In addition we used a low,
physiological testosterone dose and we did not
adjust the dose on an individual basis. In a clinical
setting the interval of the dose is usually changed
to more frequent injections, based on the patients’
physiological changes and well being.
This is the first study on androgen treatment
reporting better erectile function and sexual
quality of life in men with COPD, and, as androgen
administration did not improve the St. George’s
respiratory questionnaire, we believe this to be a
specific treatment effect. Sexual problems, speci-
fically erectile dysfunction are common in men with
COPD. Declining sexual activity is considered a
result of diverse causes. Low levels of testosterone
have been demonstrated in hypoxic COPD pa-
tients8,9 and the changes have been correlated
with the degree of hypoxemia.26 It has also been
suggested that hypoxemia suppresses the hypotha-
lamic–pituitary–testicular axis,27 and we have
previously reported that normalization of testos-
terone levels and reversal of sexual impotence may
be achieved in hypogonadal men with respiratory
failure and hypoxia who receive LTOT for 1 month.9
Androgen is necessary but not essential for normal
libido and to our knowledge its exact role in
erectile function remains unclear. Testosterone
replacement has been shown to improve quality
of erection and level of libido in patients with
erectile dysfunction.28 But in a recent study
testosterone levels were not correlated to erectile
dysfunction or the degree of erectile dysfunction.29
In the present study the level of erectile function
differed among the participantsFfrom severe erec-
tile dysfunction to normal erectile functionFand
all but one man had a total and free testosterone in
the normal range at the time of inclusion. Although
men with moderate to severe COPD compared with
healthy men have lower testosterone levels, they
may still have levels within the normal range. Thus,
the low level of biochemical hypogonadism in our
study is not surprising. COPD is a progressive
disease and during the study period testosterone
levels decreased significantly in the control group,
while increasing significantly in the treatment
group, as expected. Even though the testosterone
levels did not differ significantly between the
groups at the final visit, it is likely that the
improvement in erectile function and sexual
quality of life was caused by increased testosterone
levels.
The treatment was very well tolerated and
besides respiratory exacerbations no events were
reported that might be related to treatment. In
regards to other safety assessments, there was no
change in prostate size and PSA levels. Testoster-
one has a stimulatory effect on erytropoieses, and
some studies have reported an increase of the
hematocrit over 51% in elderly patients,30,31 but
available data suggest that the frequency of this
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Table 4 Mean (SD) levels of sex hormones, gonadotrophins, and sex hormone-binding globulin in control and
treatment groups.
Control group Treatment group
Baseline Week 12 Week 26 Baseline Week 12 Week 26
Total testosterone (nmol/l) 20.5 (5.7) 20.7 (6.3) 16.6 (6.0)w 21.6 (5.7) 19.0 (8.0) 22.8 (13.6)w
Free testosterone (pmol/l) 356 (126) 328 (85) 275 (124)w 413 (134) 367 (174) 556 (399)
LH (IU/l) 7.4 (6.7) 8.1 (5.7) 7.9 (6.7) 5.5 (3.0) 4.5 (3.1) 1.2 (1.4)nnz
FSH (IU/l) 10.6 (10.6) 10.6 (10.0) 10.1 (11.4) 6.7 (3.1) 5.2 (3.1)nz 1.3 (1.4)nnz
SHBG (nmol/l) 49.0 (15.0) 54.9 (20.5) 53.2 (20.6) 42.0 (10.0) 41.1 (11.1)n 32.4 (6.6)nz
Values at 12 weeks were obtained 4 weeks after injection and at 26 weeks 2 weeks after the final injection.
nPo0.05.
nnPo0.01 comparing delta values with control group.
wPo0.05.
zPo0.01 compared with baseline.
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side effect is related to supraphysiological levels.32
In the present study there was no increase in
hematocrit. COPD patients have an increasing
incidence of sleep disturbances and nocturnal
desaturation; Matsumoto et al.33 suggested that in
some hypogonadal men, testosterone replacement
may negatively affect ventilatory drives and induce
or worsen obstructive sleep apnea. However,
testosterone treatment was not associated with
an increase in nocturnal desaturation in our study.
Another concern has been the risk of a decrease in
HDL-cholesterol possibly increasing the risk of
ischemic heart disease. However, in agreement
with other studies, administration of testosterone
did not affect the HDL-cholesterol.34
In conclusion, administration of a low-dose
testosterone to men with moderate to severe COPD
was associated with improvement of body composi-
tion, with increased fat-free mass and reduced fat
mass. Testosterone treatment was also associated
with better erectile function and sexual quality of
life. Furthermore, there were no clinical or
biochemical side effects. Considering that for many
patients with COPD even small improvements in
well being can be of great value, treatment with
testosterone is intriguing, not least in its effect on
sexuality. However, further studies exploring this
line of treatment are warranted, especially studies
with testosterone doses adjusted on an individual
basis.
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